Abstract Body

Background: There is a “silent” population of HIV infected cells that remains in the host even after anti-retroviral therapy. This “silent” or latent population prevents the eradication of HIV in treated patients. Several mechanisms have been proposed to explain HIV latency. In order to identify the full set of cellular factors that control HIV latency, we have used a systems biology approach. Methodology: A human genome-wide shRNA library containing 25 shRNAs per gene and a complexity of 495,000 shRNAs was transduced in a Jurkat T cell model for HIV latency (J-Lat). This cell line contains a latent HIV genome with a GFP reporter. The shRNAs contain an mcherry marker for easy identification. GFP and mcherry containing double positive cells were sorted by FACS after transduction of the library. DNA was extracted from the double positive population and from the unfractionated population and analyzed by deep sequencing for the presence of unique shRNAs. shRNAs were found to be either enriched or disenriched. Results: The screen yielded several genes that have been previously reported in controlling HIV latency as well as HIV transcription. These included single genes such as MBD2, Eed and CHD1 and protein complexes such as Nurd complex and the Polycomb group complex (PrC2). Notably, the p-TEFB complex, which is the most well known positive regulator of HIV transcription, was also identified. In addition to known genes and complexes, there were also several unknown factors. These included factors that controlled T cell activation, differentiation of T cell subsets as well as T cell cytoskeletal rearrangement among others. Some of these factors have been further confirmed both in the J-Lat model as well as the primary latency model. Conclusions: The human genome wide shRNA screen yielded a broad map of the genes, complexes and pathways that could be controlling the maintenance as well as the exit from HIV latency. These novel complexes could serve as useful drug targets to test in future studies involving patient samples.